Hematologic disorders associated with hepatitis C virus infection and their management

Clinical Infectious Diseases

Volumn 37, Issue 4, 2003, Pages 533-541

  Dieterich, Douglas T ^a   Spivak, Jerry L ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; HEMOGLOBIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PREDNISOLONE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 11; RIBAVIRIN;

ANEMIA; BLOOD TOXICITY; COMORBIDITY; DISEASE ASSOCIATION; DRUG SAFETY; HEMATOLOGIC DISEASE; HEPATITIS C; HUMAN; NEUTROPENIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTOPENIA; TREATMENT CONTRAINDICATION;

ANTIVIRAL AGENTS; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOLOGIC DISEASES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-11; RECOMBINANT PROTEINS; RIBAVIRIN; UNITED STATES;

EID: 0042442463     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/376971     Document Type: Review

References (92)

1. Seef LB. Natural history of chronic hepatitis C. Hepatology 2002; 36:S35-46.
2. Strader DB, Seeff LB. Hepatitis C: a brief clinical overview. ILAR J 2001; 42:107-16.
3. Seeff LB. Natural history of hepatitis C. Am J Med 1999; 107:10S-5S.
4. National Institutes of Health. Management of hepatitis C: 2002. National Institutes of Health Consensus Development Conference Statement. Available at: http://consensus.nih.gov/cons/116/Hepc091202.pdf. Accessed 28 September 2002.
5. Fong TL, Di Bisceglie AM, Waggoner JG, et al. The significance of antibody to hepatitis C virus in patients with chronic hepatitis B. Hepatology 1991; 14:64-7.
6. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349:825-32.
7. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997; 26:62S-5S.
8. Dusheiko G, Main J, Thomas H, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996; 25:591-8.
9. Maddrey WC. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naïve patients. Semin Liver Dis 1999; 19(Suppl 1):67-75.
10. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358:958-65.
11. Rebetron (Rebetol [ribavirin]/Intron A [interferon alfa-2b, recombinant]) [package insert]. Kenilworth, NJ: Schering, 2002.
12. Spivak JL. The blood in systemic disorders. Lancet 2000; 355:1707-12.
13. Srinivasan R. Autoimmune hemolytic anemia in treatment-naïve chronic hepatitis C infection. J Clin Gastroenterol 2001; 32:245-7.
14. Chao TC, Chen CY, Yang YH, Chen PM, Chang FY, Lee SD. Chronic hepatitis C virus infection associated with primary warm-type auto-immune hemolytic anemia. J Clin Gastroenterol 2001; 33:232-3.
15. Streiff MB, Mehta S, Thomas DL. Peripheral blood count abnormalities among patients with hepatitis C in the United States. Hepatology 2002; 35:947-52.
16. Moccia F, Tognoni E, Boccaccio P. Autoimmune hemolytic anemia in chronic hepatitis C virus infection: an unusual extrahepatic autoimmune manifestation. Ann Ital Med Int 2001; 16:256-9.
17. Lai MY, Kao JH, Yang PM, et al. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996; 111:1307-12.
18. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339:1485-92.
19. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352:1426-32.
20. Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerberg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 1998; 351:83-7.
21. Verbaan HP, Widell HE, Bondeson TL, Lindgren SC. High sustained response rate in patients with histologically mild (low grade and stage) chronic hepatitis C infection: a randomized, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin. Swedish HCV Treatment Group. Eur J Gastroenterol Hepatol 2002; 14:627-33.
22. McHutchison JG, Poynard T. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin Liver Dis 1999; 19(Suppl 1):57-65.
23. Cummings KJ, Lee SM, West ES, et al. Interferon and ribavirin vs interferon alone in the retreatment of chronic hepatitis C previously nonresponsive to interferon: a meta-analysis of randomized trials. JAMA 2001; 285:193-9.
24. Chapman BA, Stace NH, Edgar CL, et al. Interferon-alpha2a/ribavirin versus interferon-alpha2a alone for the retreatment of hepatitis C patients who relapse after a standard course of interferon. N Z Med J 2001; 114:103-4.
25. de Ledinghen V, Trimoulet P, Winnock M, et al. Daily or three times per week interferon alpha-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C not responding to previous interferon alone. J Hepatol 2002; 36:819-26.
26. Kjaergard LL, Krogsgaard, Gluud C. Ribavirin with or without alpha interferon for chronic hepatitis C (Cochrane Review). Cochrane Database Syst Rev 2002; 2:CD002234.
27. Moreno-Monteagudo JA, Castro A, De Pedro A, et al. Interferon-alpha plus ribavirin for 12 months increases the sustained response rates in chronic hepatitis C relapsers. Aliment Pharmacol Ther 2002; 16:243-9.
28. Poynard T, McHutchison J, Davis GL, et al. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000; 32:1131-7.
29. Sharieff KA, Duncan D, Younossi Z. Advances in treatment of chronic hepatitis C: "pegylated" interferons. Cleve Clin J Med 2002; 69:155-9.
30. Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34:395-403.
31. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitic C virus infection. N Engl J Med 2002; 347:975-82.
32. Perry CM, Jarvis B. Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C. Drugs 2001; 61:2263-88.
33. Heathcote EJ, Shiffman ML, Cooksley WG, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343:1673-80.
34. Reddy KR, Wright TL, Pockros PJ, et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in non-cirrhotic patients with chronic hepatitis C. Hepatology 2001; 33:433-8.
35. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343:1666-72.
36. Hadziyannis SJ, Cheinquer H, Morgan T, et al. Peginterferon alfa-2a (40KD) (PEGASYS) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and RBV dose [abstract 536]. J Hepatol 2002; 26(Suppl 1):3.
37. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123:1061-9.
38. McHutchison JG. Hepatitis C advances in antiviral therapy: what is accepted treatment now? J Gastroenterol Hepatol 2002; 17:431-41.
39. Peck-Radosavljevic M, Wichlas M, Homoncik-Kraml M, et al. Rapid suppression of hematopoiesis by standard or pegylated interferon-α. Gastroenterology 2002; 123:141-51.
40. Soza A, Everhart JE, Ghany MG, et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology 2002; 36:1273-9.
41. PEG-Intron (peginterferon alfa-2b) [package insert]. Kenilworth, NJ: Schering, 2002.
42. Pegasys (peginterferon alfa-2a, recombinant) [package insert]. Nutley, NJ: Hoffman-LaRoche, 2002.
43. Roferon-A (interferon alfa-2a, recombinant) [package insert]. Nutley, NJ: Hoffman-LaRoche, 2002.
44. Canonico PG, Kastello MD, Cosgriff TM, et al. Hematological and bone marrow effects of ribavirin in rhesus monkeys. Toxicol Appl Pharmacol 1984; 74:163-72.
45. de Franceschi L, Fattovich G, Turrini F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000; 31:997-1004.
46. Van Vlierbergh H, Delanghe JR, De Vos M, Leroux-Roel G. Factors influencing ribavirin-induced hemolysis. BASL Steering Committee. J Hepatol 2001; 34:911-6.
47. Kurschel E, Metz-Kurschel U, Niederle N, Aulbert E. Investigations on the subclinical and clinical nephrotoxicity of interferon alpha-2B in patients with myeloproliferative syndromes. Ren Fail 1991; 13:87-93.
48. Sacchi S, Kantarjian H, O'Brien S, Cohen PR, Pierce S, Talpaz M. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J Clin Oncol 1995; 13:2401-7.
49. Tarumi T, Sawada K, Sato N, et al. Interferon-alpha-induced apoptosis in human erythroid progenitors. Exp Hematol 1995; 23:1310-8.
50. Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998; 16:3412-25.
51. Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001; 19: 2875-82.
52. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. Epoetin alfa Study Group. J Clin Oncol 2001; 19:2865-74.
53. Moore R. Human immunodeficiency virus infection, anemia, and survival. Clin Infect Dis 1999; 29:44-9.
54. Revicki DA, Brown RE, Henry DH, McNeill MV, Rios A, Watson T. Recombinant human erythropoietin and health-related quality of life of AIDS patients with anemia. J Acquir Immune Defic Syndr 1994; 7:474-84.
55. Mocroft A, Kirk O, Barton SE, et al. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. AIDS 1999; 13:943-50.
56. Sagir A, Wettstein M, Heintges T, Haussinger D. Autoimmune thrombocytopenia induced by PEG-IFN-alpha2b plus ribavirin in hepatitis C. Dig Dis Sci 2002; 47:562-3.
57. Bommer J, Alexiou C, Muller-Buhl U, Eifert J, Ritz E. Recombinant human erythropoietin therapy in haemodialysis patients - dose determination and clinical experience. Nephrol Dial Transplant 1987; 2:238-42.
58. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: results of a combined phase I and II clinical trial. N Engl J Med 1987; 316:73-8.
59. Abrams DI, Steinhart C, Frascino R. Epoetin alfa therapy for anemia in HIV-infected patients: impact on quality of life. Int J STD AIDS 2000; 11:659-65.
60. Fischl M, Galpin JE, Levine JD, et al. Recombinant human erythropoietin for patients with AIDS treated with zidovudine. N Engl J Med 1990; 322:1488-93.
61. + patients [abstract 254]. 010 Study Group. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2001:322.
62. Henry DH, Beall GN, Benson CA, et al. Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy: overview of four clinical trials. Ann Intern Med 1992; 117:739-48.
63. + patients [abstract 708]. CHAMPS Study Group. In: Program and abstracts of the 39th annual meeting of the Infectious Diseases Society of America (San Francisco). Alexandria, VA: Infectious Diseases Society of America, 2001:1209.
64. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997; 15:1218-34.
65. Henry DH, Abels RI. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies. Semin Oncol 1994; 21(Suppl 3):21-8.
66. Quirt I, Robeson C, Lau CY, et al. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol 2001; 19:4126-34.
67. Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. The US Recombinant Human Erythropoietin Predialysis Study Group. Am J Kidney Dis 1991; 18:50-9.
68. Gergely AE, Lafarge P, Fouchard-Hubert I, Lunel-Fabiana F. Treatment of ribavirin/interferon-induced anemia with erythropoietin in patients with hepatitis C. Hepatology 2002; 35:1281-2.
69. Sulkowski M, Wasserman R, Brau N, Hassanein T, Bini E, Dieterich D. Once-weekly recombinant human erythropoietin (epoetin alfa) facilitates optimal ribavirin (RBV) dosing in hepatitis C virus-infected patients receiving interferon-α-2b (IFN)/RBV therapy [abstract 18]. In: Program and abstracts of the Hepatitis Single Topic Conference (Chicago). Alexandria, VA: American Association for the Study of Liver Diseases, 2001:66.
70. Talal AH, Weisz K, Hau T, Kreiswirth S, Dieterich DT. A preliminary study of erythropoietin for anemia associated with ribavirin and interferon-α. Am J Gastroenterol 2001; 96:2802-4.
71. Ware JE Jr, Kosinski M, Keller SD. A 12 item short form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996; 34:220-33.
72. Neupogen (recombinant human G-CSF, filgrastim) [package insert]. Thousand Oaks, CA: Amgen, 2002.
73. Ozer H, Armitage JO, Bennett CL, et al. 2000 Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 2000; 18:3558-85.
74. Gabrilove JL, Jakubowski A, Scher H, et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional cell carcinoma of the urothelium. N Engl J Med 1988; 318:1414-22.
75. Heil G, Hoelzer D, Sanz MA, et al. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission, induction, and consolidation therapy for adults with de novo acute myeloid leukemia. Blood 1997; 90:4710-8.
76. Fukuda A, Kobayashi H, Teramura K, Yoshimoto S, Ohsawa N. Effects of interferon-alpha on peripheral neutrophil counts and serum granulocyte colony-stimulating factor levels in chronic hepatitis C patients. Cytokines Cell Mol Ther 2000; 6:149-54.
77. Van Thiel DH, Faruki H, Friedlander L, et al. Combination treatment of advanced HCV associated liver disease with interferon and G-CSF. Hepatogastroenterology 1995; 42:907-12.
78. Sood A, Reddy N, Russo MW, Brown RS, Jacobson IM. Use of granulocyte colony stimulating factor (GCSF) for interferon induced neutropenia in patients with chronic hepatitis C infection [abstract 1029]. In: Program and abstracts of the 52nd annual meeting of the American Association for the Study of Liver Diseases (Dallas, TX). Alexandria, VA: American Association for the Study of Liver Diseases, 2001:429A.
79. Hepatitis Resource Network. Management of side effects in hepatitis C treatment. 2001. Available at: http://www.h-r-n.org]provider/algorithms/hcvalgo1011.pdf. Accessed 10 December 2002.
80. Neulasta (pegylated recombinant human G-CSF; pegfilgrastim) [package insert]. Thousand Oaks, CA: Amgen, 2002.
81. Neumega (recombinant human IL-11; oprelvekin) [package insert]. Cambridge, MA: Genetics Institute, 2002.
82. Gordon MS, McCaskill-Stevens WJ, Battiato LA, et al. A phase I trial of recombinant human interleukin-11 (Neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. Blood 1996; 87:3615-24.
83. Isaacs C, Robert NJ, Bailey FA, et al. Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. J Clin Oncol 1997; 15:3368-77.
84. Dykstra KH, Rogge H, Stone A, Loewy J, Keith JC, Schwertschlag US. Mechanism and amelioration of recombinant human interleukin-11 (rhIL-11) -induced anemia in healthy subjects. J Clin Pharmacol 2000; 40:880-8.
85. Rustgi VK, Lee P, Finnegan S, Ershler W. Safety and efficacy of recombinant human IL-11 (oprelvekin) in combination with interferon/ribavirin therapy in hepatitis C patients with thrombocytopenia [abstract 791]. In: Program and abstracts of the 53rd annual meeting of the American Association for the Study of Liver Diseases (Boston). Alexandria, VA: American Association for the Study of Liver Diseases, 2002:361A.
86. Poynard T, Cacoub P, Ratziu V, et al. Fatigue in patients with chronic hepatitis C. J Viral Hepat 2002; 9:295-303.
87. Piche T, Gelsi E, Schneider SM, et al. Fatigue is associated with high circulating leptin levels in chronic hepatitis C. Gut 2002; 51:434-9.
88. Hambleton J. Hematologic complications of HIV infection. Oncology 1996; 10:671-80.
89. Radkowski M, Kubicka J, Kisiel E, et al. Detection of active hepatitis C virus and hepatitis G virus/GB virus C replication in bone marrow in human subjects. Blood 2000; 95:3986-9.
90. Rajan S, Liebman HA. Treatment of hepatitis C related thrombocytopenia with interferon alpha. Am J Hematol 2001; 68:202-9.
91. Benci A, Caremani M, Tacconi D. Thrombocytopenia in patients with HCV-positive chronic hepatitis: efficacy of leucocyte interferon-alpha treatment. Int J Clin Pract 2003; 57:17-9.
92. Garcia-Suarez J, Burgaleta C, Hernanz N, Albarran F, Tobaruela P, Alvarez-Mon M. HCV-associated thrombocytopenia: clinical characteristics and platelet response after recombinant alpha-2b-interferon therapy. Br J Haematol 2000; 110:98-103.